Toripalimab trials for Colorectal cancer

All Toripalimab trials · All Colorectal cancer trials

Phase breakdown

Recruiting trials studying Toripalimab for Colorectal cancer

• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
  NCT06547203 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
  NCT07281716 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
  NCT07140679 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
  NCT07277322 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
  NCT05963490 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Toripalimab for Colorectal cancer?

6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.